for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Syros Pharmaceuticals Inc

SYRS.O

Latest Trade

5.22USD

Change

0.00(-0.00%)

Volume

1,109,270

Today's Range

5.13

 - 

5.42

52 Week Range

4.75

 - 

15.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.22
Open
5.18
Volume
1,109,270
3M AVG Volume
15.56
Today's High
5.42
Today's Low
5.13
52 Week High
15.65
52 Week Low
4.75
Shares Out (MIL)
61.86
Market Cap (MIL)
322.90
Forward P/E
-3.53
Dividend (Yield %)
--

Next Event

Syros Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Syros Reports Q1 Loss Per Share Of $0.23

Syros Pharma Reports Q4 Loss Per Share Of $0.62

Syros Announces Pricing Of $75.6 Mln Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Industry

Business Services

Contact Info

35 CAMBRIDGE PARK DRIVE

CAMBRIDGE, MA

02140

United States

+1.617.7441340

https://syros.com/

Executive Leadership

Peter Wirth

Independent Chairman of the Board

Nancy A. Simonian

President, Chief Executive Officer, Director

Joseph J. Ferra

Chief Financial Officer

Eric R. Olson

Chief Scientific Officer

Gerald E. Quirk

Chief Legal & Administrative Officer

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.910

2019

-1.880

2020

-1.820

2021(E)

-1.477
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.41
Price To Book (MRQ)
2.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
26.87
LT Debt To Equity (MRQ)
26.69
Return on Investment (TTM)
-43.24
Return on Equity (TTM)
-38.41

Latest News

Latest News

BRIEF-Syros Pharmaceuticals Says Entered Into A Sales Agreement With Cowen & Company, Dated June 12

* SYROS PHARMACEUTICALS INC - ENTERED INTO A SALES AGREEMENT WITH COWEN & COMPANY, DATED JUNE 12

BRIEF-Syros Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing

* SYROS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING Source text for Eikon: https://bit.ly/3dXPST3 Further company coverage:

BRIEF-Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program

* SYROS PHARMACEUTICALS INC - PRESENTS NEW PRECLINICAL DATA HIGHLIGHTING THERAPEUTIC POTENTIAL OF SY-5609 IN COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Syros Pharmaceuticals Q1 Loss Per Share $0.39

* SYROS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES

BRIEF-Syros Pharma To Sell Shares Of Co's Common Stock Of Up To $50 Mln

* SYROS PHARMACEUTICALS - TO OFFER AND SELL SHARES OF CO'S COMMON STOCK OF UP TO $50 MILLION THROUGH COWEN, ACTING AS CO'S AGENT - SEC FILING Source text: (http://bit.ly/2Q9zw07) Further company coverage:

BRIEF-Syros Reports Q4 Loss Per Share $0.46

* SYROS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES

BRIEF-Syros Announces $60 Million Loan Facility With Oxford Finance Llc

* SYROS ANNOUNCES $60 MILLION LOAN FACILITY WITH OXFORD FINANCE LLC

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up